Is Cancer a Genetic Disease or a Metabolic Disease?

EBioMedicine

Volumn 2, Issue 6, 2015, Pages 478-479

  Wishart, David S ^a,b  

^a UNIVERSITY OF ALBERTA   (Canada)

^b NATIONAL RESEARCH COUNCIL CANADA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

2 HYDROXYGLUTARIC ACID; ANTINEOPLASTIC ANTIMETABOLITE; ASPARAGINE; CHOLINE; DICHLOROACETIC ACID; FUMARIC ACID; GLUCOSE; GLUTAMINE; GLYCINE; LACTIC ACID; METFORMIN; POLYAMINE; RITONAVIR; SARCOSINE; SERINE; SUCCINIC ACID; TETRAHYDROLIPSTATIN;

CANCER GENETICS; CANCER MORTALITY; DIET; GENE MUTATION; GENETIC ANALYSIS; HUMAN; METABOLISM; NEOPLASM; NOTE; ONCOGENE; PHENOTYPE; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE; CELLS; GENETIC PREDISPOSITION; GENETICS; METABOLIC DISORDER;

CELLS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; METABOLIC DISEASES; NEOPLASMS;

EID: 84949624359     PISSN: None     EISSN: 23523964     Source Type: Journal    
DOI: 10.1016/j.ebiom.2015.05.022     Document Type: Note

References (10)

1. Boroughs L.K., DeBerardinis R.J. Metabolic pathways promoting cancer cell survival and growth. Nat. Cell Biol. 2015, 17:351-359.
2. Forbes S.A., Beare D., Gunasekaran P., Leung K., Bindal N., Boutselakis H., Ding M., Bamford S., Cole C., Ward S., Kok C.Y., Jia M., De T., Teague J.W., Stratton M.R., McDermott U., Campbell P.J. COSMIC: exploring the world's knowledge of somatic mutations in human cancer. Nucleic Acids Res. 2015, 43:D805-D811. (Database issue).
3. Kolata, G., 2009. In long drive to cure cancer, advances have been elusive. The New York Times, April 23.
4. Lee W., Jiang Z., Liu J., Haverty P.M., Guan Y., Stinson J., Yue P., Zhang Y., Pant K.P., Bhatt D., Ha C., Johnson S., Kennemer M.I., Mohan S., Nazarenko I., Watanabe C., Sparks A.B., Shames D.S., Gentleman R., de Sauvage F.J., Stern H., Pandita A., Ballinger D.G., Drmanac R., Modrusan Z., Seshagiri S., Zhang Z. The mutation spectrum revealed by paired genome sequences from a lung cancer patient. Nature 2010, 465:473-477.
5. 11C]-glutamine for metabolic imaging of tumors. J. Nucl. Med. 2012, 53:98-105.
6. Surveillance, Epidemiology, and End Results (SEER) Program () Research Data, National Cancer Institute, DCCPS, Surveillance Research Program, Surveillance Systems Branch, released April 2015. http://www.seer.cancer.gov.
7. Seyfried T. Cancer as metabolic disease: on the origin, management, and prevention of cancer 2012, Wiley, Hoboken NJ, (438 pp.).
8. Wang H., Tso V., Wong C., Sadowski D., Fedorak R.N. Development and validation of a highly sensitive urine-based test to identify patients with colonic adenomatous polyps. Clin. Transl. Gastroenterol. 2014, 5:e54.
9. Ward P.S., Patel J., Wise D.R., Abdel-Wahab O., Bennett B.D., Coller H.A., Cross J.R., Fantin V.R., Hedvat C.V., Perl A.E., Rabinowitz J.D., Carroll M., Su S.M., Sharp K.A., Levine R.L., Thompson C.B. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell 2010, 17:225-234.
10. Xie G., Lu L., Qiu Y., Ni Q., Zhang W., Gao Y.T., Risch H.A., Yu H., Jia W. Plasma metabolite biomarkers for the detection of pancreatic cancer. J. Proteome Res. 2015, 14:1195-1202.